GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis - Guttman-Yassky, Emma; Pavel, Ana B.; Zhou, Lisa; Estrada, Yeriel D.; Zhang, Ning; Xu, Hui; Peng, Xiangyu; Wen, Huei-Chi; Govas, Panayiota; Gudi, Girish; CA, Vinu; Fang, Hui; et al. (Journal of allergy and clinical immunology, 2019)
Keywords: Adult; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Apoptosis; Atopic dermatitis; biomarkers; Biopsy; CCL17 protein; costimulation; CXCL10 protein; Cytokines; Cytokines - immunology; Dendritic cells; Dermatitis; Dermatitis, Atopic - drug therapy; Dermatitis, Atopic - immunology; Dermatitis, Atopic - pathology; Eczema; FDA approval; Female; Gene expression; Gene Expression Regulation - drug effects; Gene Expression Regulation - immunology; Helper cells; Humans; Hyperplasia; Hyperplasia - immunology; Hyperplasia - pathology; inflammation; Interleukin 8; Intravenous administration; Keratin; Lymphocytes; Lymphocytes T; Male; Middle Aged; Monoclonal antibodies; OX40; Ox40L protein; Patients; Population; Pruritus; Psoriasis; Receptors, OX40 - antagonists & inhibitors; Receptors, OX40 - immunology; Skin; Skin - immunology; Skin - pathology; Skin diseases; TH1; TH17/TH22; TH2; trial; γ-Interferon; United States--US; OX40; DLQI; OX40L; ITT; trial; NRS; BSA; EASI; costimulation; Atopic dermatitis; inflammation; hyperplasia; SCORAD; IGA; AD; TSLP; biomarkers; TSLPR; K16; TEAE; BAS; TH17/TH22; TH1; Foxp3; TH2; DC; T(H)17/T(H)22; T(H)1; T(H)2